{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:40:50Z","timestamp":1788910850507,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The burden of chronic obstructive pulmonary disease (COPD) in people who experience frequent moderate\/severe exacerbations and frequent productive cough (FPC) while receiving triple inhaled therapy (TT) is poorly described. We aimed to examine clinical characteristics and patient-centric burden of this population. Methods: Data were drawn from the Adelphi COPD Disease-Specific Programme (DSP)\u2122, a multinational cross-sectional survey on COPD (July 2022\u2013January 2023). Patient characteristics and physician perceptions were described for the overall COPD cohort and subsets of those who were current\/former Smokers, with \u22652 moderate or \u22651 severe Exacerbation(s) in the prior year while receiving TT and with FPC (SET+FPC) or without FPC (SET w\/o FPC). Results: Of the overall cohort (N = 4372), 9.1% (n = 399) patients qualified for inclusion in the SET+FPC cohort; the mean (SD) age was 64.7 (10.9) and 69.1 (9.2) years, respectively. For the overall and SET+FPC cohorts, the mean (SD) number of exacerbations (prior year) was 1.1 (1.4) and 2.5 (1.4), respectively; median post-bronchodilator forced expiratory volume in 1 s (FEV1% predicted) was 68.0% and 49.0%, respectively, and physician-reported dyspnea grade (based on the modified Medical Research Council Dyspnea Scale) was \u22652 in 36.2% and 78.2%, respectively. Physicians were satisfied with COPD control in 76.1% of the overall and 39.6% of the SET+FPC cohorts. Conclusions: People with COPD who experience frequent moderate\/severe exacerbations and FPC while receiving TT have substantial clinical and patient-centric burden and extensive unmet medical needs, suggesting inadequate disease control with current standard-of-care therapies.<\/jats:p>","DOI":"10.3390\/jcm14186488","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T11:51:43Z","timestamp":1757937103000},"page":"6488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Burden of People with Symptomatic and Exacerbating COPD While on Triple Inhaled Therapy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0344","authenticated-orcid":false,"given":"Anthony","family":"De Soyza","sequence":"first","affiliation":[{"name":"Population and Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Nordon","sequence":"additional","affiliation":[{"name":"Global Medical Evidence, AstraZeneca, Cambridge CB2 0AA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Coak","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington SK10 5JB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia","family":"Pennant","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington SK10 5JB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Mullerova","sequence":"additional","affiliation":[{"name":"Global Medical Evidence, AstraZeneca, Cambridge CB2 0AA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Fageras","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, AstraZeneca, 43183 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Andre","family":"Alves","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, AstraZeneca, 43183 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-2982","authenticated-orcid":false,"given":"Wim","family":"Janssens","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University Hospital Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: Time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/COPD.S142378","article-title":"Prediction models for exacerbations in different COPD patient populations: Comparing results of five large data sources","volume":"12","author":"Hoogendoorn","year":"2017","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.12.014","article-title":"Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life","volume":"73","author":"Hurst","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: Progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1164\/rccm.201210-1843CI","article-title":"Chronic bronchitis and chronic obstructive pulmonary disease","volume":"187","author":"Kim","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","first-page":"127","article-title":"Disease onset and burden in patients with chronic bronchitis and COPD: A Real-World Evidence Study","volume":"12","author":"Krishnan","year":"2025","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Choi, J.Y., Yoon, H.K., Lee, S.Y., Kim, J.W., Choi, H.S., Kim, Y.-I., Jung, K.-S., Yoo, K.H., Kim, W.J., and Rhee, C.K. (2022). Comparison of clinical characteristics between chronic bronchitis and non-chronic bronchitis in patients with chronic obstructive pulmonary disease. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-01854-x"},{"key":"ref_9","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (2024, May 28). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). Available online: https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/COPD.S423993","article-title":"Real-world disease burden and healthcare resource utilization among patients with COPD and asthma using triple therapy (FF\/UMEC\/VI) in the United States","volume":"19","author":"Igboekwe","year":"2024","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2147\/COPD.S163717","article-title":"Symptomatic burden of COPD for patients receiving dual or triple therapy","volume":"13","author":"Chen","year":"2018","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: A biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100306","DOI":"10.1016\/j.opresp.2024.100306","article-title":"Biologics in COPD","volume":"6","author":"Kersul","year":"2024","journal-title":"Open Respir. Arch."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Plichta, J., Kuna, P., and Panek, M. (2023). Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: Recent developments and future perspectives. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1207641"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2024.05.011","article-title":"Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins","volume":"125","author":"Varricchi","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155891","DOI":"10.1016\/j.cyto.2022.155891","article-title":"Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine","volume":"156","author":"Cayrol","year":"2022","journal-title":"Cytokine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2014A means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: An update on Disease Specific Programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: The Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: A long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","first-page":"A68","article-title":"S92\u2005FRONTIER-4: A phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD","volume":"79","author":"Singh","year":"2024","journal-title":"Thorax"},{"key":"ref_24","first-page":"178","article-title":"Chronic Bronchitis: Where are we now?","volume":"6","author":"Dotan","year":"2019","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106921","DOI":"10.1016\/j.rmed.2022.106921","article-title":"Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and\/or COPD in the NOVELTY study","volume":"200","author":"Hughes","year":"2022","journal-title":"Respir. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.00125612","article-title":"Comparisons of health status scores with MRC grades in COPD: Implications for the GOLD 2011 classification","volume":"42","author":"Jones","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_27","first-page":"PA1288","article-title":"Characteristics of exacerbating COPD patients with productive cough and on inhaled triple therapy, by smoking status: A real-world multi-country study","volume":"64","author":"Janssens","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_28","first-page":"PA1289","article-title":"Perception of COPD control by physicians managing symptomatic exacerbating patients receiving inhaled triple therapy: A real-world multi-country 2022 survey","volume":"64","author":"Nordon","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_29","first-page":"CD010744","article-title":"Smoking cessation for people with chronic obstructive pulmonary disease","volume":"2016","author":"Kotz","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"00697","DOI":"10.1183\/23120541.00697-2023","article-title":"Chronic cough associated with COPD exacerbation, pneumonia and death in the general population","volume":"10","author":"Landt","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12931-017-0548-3","article-title":"Understanding the impact of symptoms on the burden of COPD","volume":"18","author":"Miravitlles","year":"2017","journal-title":"Respir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.chest.2023.11.033","article-title":"Silent airway mucus plugs in COPD and clinical implications","volume":"166","author":"Mettler","year":"2024","journal-title":"Chest"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/09031936.00177210","article-title":"Properties of the COPD assessment test in a cross-sectional European study","volume":"38","author":"Jones","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_35","unstructured":"EUROQOL 2024 (2024, July 02). EUROQOL: Population Norms. Available online: https:\/\/euroqol.org\/information-and-support\/resources\/population-norms\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/COPD.S378649","article-title":"Patients with chronic obstructive pulmonary disease and evidence of eosinophilic inflammation experience exacerbations despite receiving maximal inhaled maintenance therapy","volume":"17","author":"Chen","year":"2022","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6488\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:40Z","timestamp":1760035540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":36,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14186488"],"URL":"https:\/\/doi.org\/10.3390\/jcm14186488","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}